The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder
- PMID: 14624805
- DOI: 10.1016/j.neubiorev.2003.08.012
The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder
Abstract
There is evidence that abnormalities within the dopamine system in the brain play a major role in the pathophysiology of attention deficit hyperactivity disorder (ADHD). For instance, dopaminergic psychostimulants, the drugs of first choice in ADHD, interact directly with the dopamine transporter (DAT). Molecular genetic studies suggest involvement of a polymorphism of the DAT gene in ADHD. More recent imaging studies show abnormalities in various brain structures, but particularly in striatal regions. In the current paper we review recent studies in this area. First in vivo measurements of DAT with single photon emission computed tomography (SPECT) in ADHD patients revealed an elevation of striatal DAT density. No differences in DAT density between the left and right side and between putamen and caudate nucleus have been found in [99mTc]TRODAT-1 SPECT of ADHD patients. Patients with ADHD and with a history of nicotine abuse both displayed lower values of DAT density in [99mTc]TRODAT-1 SPECT than non-smokers with ADHD. DAT seem to be elevated in non-smoking ADHD patients suffering from the purely inattentive subtype of ADHD as well as in those with the combined or purely hyperactive/impulsive subtype.
Similar articles
-
Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder.Int J Neuropsychopharmacol. 2002 Jun;5(2):111-3. doi: 10.1017/S1461145702002821. Int J Neuropsychopharmacol. 2002. PMID: 12135534 Clinical Trial.
-
Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.Biol Psychiatry. 2005 Feb 1;57(3):229-38. doi: 10.1016/j.biopsych.2004.11.009. Biol Psychiatry. 2005. PMID: 15691523
-
Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment.Eur J Nucl Med. 2000 Oct;27(10):1518-24. doi: 10.1007/s002590000330. Eur J Nucl Med. 2000. PMID: 11083541
-
SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder.Expert Rev Neurother. 2008 Apr;8(4):611-25. doi: 10.1586/14737175.8.4.611. Expert Rev Neurother. 2008. PMID: 18416663 Review.
-
The dopamine transporter and attention-deficit/hyperactivity disorder.Biol Psychiatry. 2005 Jun 1;57(11):1397-409. doi: 10.1016/j.biopsych.2004.10.011. Epub 2005 Jan 5. Biol Psychiatry. 2005. PMID: 15950014 Review.
Cited by
-
Increased dopamine transporter function as a mechanism for dopamine hypoactivity in the adult infralimbic medial prefrontal cortex following adolescent social stress.Neuropharmacology. 2015 Oct;97:194-200. doi: 10.1016/j.neuropharm.2015.05.032. Epub 2015 Jun 6. Neuropharmacology. 2015. PMID: 26056032 Free PMC article.
-
Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD007986. doi: 10.1002/14651858.CD007986.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2023 Apr 14;4:CD007986. doi: 10.1002/14651858.CD007986.pub3. PMID: 22786509 Free PMC article. Updated.
-
Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD007986. doi: 10.1002/14651858.CD007986.pub3. Cochrane Database Syst Rev. 2023. PMID: 37058600 Free PMC article.
-
Prefrontal cortical α2A-adrenoceptors and a possible primate model of attention deficit and hyperactivity disorder.Neurosci Bull. 2015 Apr;31(2):227-34. doi: 10.1007/s12264-014-1514-4. Epub 2015 Mar 31. Neurosci Bull. 2015. PMID: 25822217 Free PMC article. Review.
-
Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients.Eur Arch Psychiatry Clin Neurosci. 2006 Mar;256(2):115-21. doi: 10.1007/s00406-005-0618-2. Epub 2005 Nov 15. Eur Arch Psychiatry Clin Neurosci. 2006. PMID: 16284713
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical